| Literature DB >> 34579772 |
Huanrui Hu1,2, Yuwei Xiang1, Bin Huang1, Ding Yuan1, Yi Yang1, Jichun Zhao3.
Abstract
BACKGROUND: Carotid body tumors (CBTs) are rare neuroendocrine neoplasms, but the prognosis of patients with resected CBTs has seldom been elucidated. This study was conducted to investigate the association between variables, especially sex, and the prognosis of carotid body tumor resection.Entities:
Keywords: Carotid body tumor; Gender; Prognosis; Surgery outcomes
Mesh:
Year: 2021 PMID: 34579772 PMCID: PMC8477547 DOI: 10.1186/s40463-021-00540-y
Source DB: PubMed Journal: J Otolaryngol Head Neck Surg ISSN: 1916-0208
Patient Demographics and Tumor Characteristics
| Characteristic | Male (n = 109) | Female (n = 217) | |
|---|---|---|---|
| Total tumor number | 126 | 252 | |
| Tumor size (cm) | 4.3 ± 1.8 | 3.8 ± 1.4 | .003 |
| Age at diagnosis (years) | 47.6 ± 13.9 | 47.3 ± 12.3 | .856 |
| Symptoms | |||
| Neck mass | 72 (66.1) | 137 (63.1) | .627 |
| Dysphagia | 5 (4.6) | 7 (3.2) | .544 |
| Tinnitus | 1 (0.9) | 6 (2.8) | .431 |
| Hoarseness | 8 (7.3) | 9 (4.1) | .290 |
| Horner syndrome | 3 (2.8) | 10 (4.6) | .555 |
| Tongue paralysis | 11 (10.1) | 18 (8.3) | .681 |
| Tumor location | |||
| Left-side | 40 | 96 | .193 |
| Right-side | 52 | 100 | .782 |
| Bilateral | 17 | 28 | .506 |
| Shamblin classification | |||
| I | 16 (14.6) | 41 (18.9) | .284 |
| II | 43 (39.4) | 81 (37.3) | .890 |
| III | 50 (45.9) | 95 (43.8) | .928 |
| SDHB gene screen | 51 (46.8) | 106 (48.8) | .726 |
| Mutation positive | 12 (23.5) | 9 (8.5) | .019 |
| Local invasion | 27 (24.8) | 51 (23.6) | .800 |
Data are presented as n (%) or mean ± SD unless stated otherwise
Surgical outcomes and Follow-up
| Univariate variables | Male (n = 109) | Female (n = 217) | |
|---|---|---|---|
| EBL (ml) | 974.0 ± 763.2 | 690.8 ± 583.7 | .021 |
| Perioperative complications | |||
| Cerebral infarction | 2 (1.8) | 5 (2.3) | 1.000 |
| Postoperative hypotension | 1 (0.9) | 3 (1.4) | 1.000 |
| Laryngeal obstruction | 1 (0.9) | 0 | .334 |
| Nerve injury* | |||
| Any nerve injury | 45 (38.5) | 58 (26.7) | .008 |
| Facial nerve | 7 (6.4) | 10 (4.6) | .667 |
| Glossopharyngeal nerve | 4 (3.6) | 12 (5.5) | .592 |
| Vagus nerve | 29 (26.6) | 36 (16.6) | .032 |
| Accessory nerve | 3 (2.8) | 4 (1.8) | .690 |
| Hypoglossal nerve | 35 (32.1) | 44 (20.2) | .019 |
| Superior laryngeal nerve | 3 (2.8) | 4 (1.8) | .690 |
| Recurrent laryngeal nerve | 1 (0.9) | 3 (1.4) | 1.000 |
| Multiple nerves injuries | 25 (22.9) | 31 (14.2) | .051 |
| Perioperative mortality | 0 | 1 (0.5) | 1.000 |
| Follow-up (mo) | 62.5 ± 33.6 | 60.5 ± 33.6 | .601 |
| Local recurrence | 15 (13.8) | 12 (5.5) | .011 |
| Distant metastasis | 18 (16.5) | 17 (7.8) | .096 |
| Stroke | 8 (7.3) | 15 (6.9) | .554 |
| Permanent nerve injury | 18 (16.5) | 23 (10.6) | .330 |
| Deceased | 7 (6.4) | 8 (3.7) | .220 |
| Withdraw | 9 (8.3) | 14 (6.4) | .548 |
Data are presented as n (%) or mean ± SD unless stated otherwise
*Include Horner syndrome, hoarseness, dysphagia, tongue muscle atrophy, local paralysis, EBL Estimated blood loss
Correlation between variables and estimated blood loss
| Female# | Age* | Maximal diameter* | Shamblin grade# | SDHB mutation# | Preoperative neurological symptoms# | |
|---|---|---|---|---|---|---|
| Coefficient | − .106 | − .026 | .612 | .461 | − .142 | .102 |
| .226 | .767 | < .001 | < .001 | .403 | .248 |
*Pearson correlation was used for continuous variables
#Spearman correlation was used for binary variables
Multivariate logistic regression with risk factors for any nerve injury
| Variables | OR | 95%CI | |
|---|---|---|---|
| Female | 1.00 | 0.39–2.53 | .079 |
| Age | 0.99 | 0.94–1.05 | .857 |
| Maximal diameter | 1.96 | 1.67–2.38 | .004 |
| Shamblin grade | 6.06 | 2.34–15.65 | < .001 |
| SDHB mutation | 2.78 | 0.83–3.33 | .420 |
| Preoperative neurological symptoms | 1.33 | 0.30–5.88 | .157 |
OR odd ratio; CI confidence interval;
Fig. 1Kaplan–Meier analysis demonstrated males had shorter relapse-free survival (P = .021)
Multivariate cox regression between variables and follow-up outcomes
| Deceased (HR, 95% CI) | RFS (HR, 95% CI) | |
|---|---|---|
| Female | 0.13, 0.02–1.51 | 0.78, 0.50–0.86* |
| Maximal diameter | 1.03, 0.35–3.03 | 1.05, 0.63–1.75 |
| Shamblin grade | 2.52, 0.80–3.15 | 1.08, 0.38–3.03 |
| SDHB mutation | 3.86, 0.33–45.45 | 3.52, 1.11–11.14* |
| Remote metastasis | 4.01, 1.66–8.28* | |
| Local recurrence | 6.46, 2.30–9.61* | |
| Stroke | 1.62, 0.48–4.04 |
HR hazard ratio; CI confidence interval
*P < .05; RFS: relapse free survival